Quantitative Cardiac Magnetic Resonance Imaging in Finding Heart Complications in Patients with Breast Cancer Receiving Chemotherapy
- Histologic diagnosis of breast carcinoma
- Scheduled to receive standard clinical therapy designed by their treating oncologist
- Patients should receive anthracycline as part of the recommended treatment
- Able to give informed consent
- Contraindication to contrast CMR including estimated glomerular filtration rate (eGFR) < 30 mls/min/1.73 m^2
- Uncontrolled serious concurrent illness
- Pregnancy or breast feeding
I. To quantify the distributions and temporal changes of cardiac magnetic resonance (CMR) parameters during chemotherapy.
II. To identify CMR predictors of cardiotoxicity in patients receiving anthracycline +/- neoadjuvant therapy.
III. Demonstrate the incremental predictive value of CMR versus (vs.) transthoracic echocardiogram (TTE) and serum biomarkers in cardiotoxicity.
Patients undergo CMR at baseline, after completion anthracycline treatment, immediately after completion of all treatments (patients may receive targeted HER2+ positive treatment or other treatments between 3rd and 4th scans), and 12 months after completion of treatment.
After completion of study treatment, patients are followed up in 1 and 2 year intervals.
Trial Phase Phase NA
Trial Type Screening
Dana-Farber Harvard Cancer Center
- Primary ID 15-017
- Secondary IDs NCI-2016-00297
- Clinicaltrials.gov ID NCT02666378